Good Therapeutics
acquired by RocheSeattle, US · Founded 2016 · Delaware corporation · 3 known investors
Find your way into Good Therapeutics
524 people in our graph share verified history with the Good Therapeutics team — schools, employers, funds. One of them is your warm intro.
Mike Volpiunlockedknows John Mulligan · together at Stanford University (overlapped)
×8knows the team · via Stanford University
knows the team · via Bonum Therapeutics
×2knows the team · via Massachusetts Institute of Technology
Portfolio company acquired by Roche.
Founders & leadership
Good Therapeutics was founded in 2016 by John Mulligan.
JM
John MulliganinFounderJohn Mulligan held early-stage roles at multiple drug discovery and synthetic biology companies, including Darwin Molecular where he contributed to the discovery of an osteoporosis drug target using human genetics, and Glycostasis where he developed a glucose-responsive insulin technology. He served as CEO of Good Therapeutics, which was acquired by Roche in 2022, and currently leads Bonum Therapeutics and co-founded Nagoon Therapeutics, both focused on therapeutic protein engineering.
MM
Mitchell MutzNamed on SEC filing
NW
Nicholas WalrodNamed on SEC filing
Board
JM
John McKearnin𝕏Board directorSenior Advisor at RiverVest Venture Partners, focused on early-stage biotech
KH
Karl HandelsmanBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$31.1M disclosed across 2 of 4 rounds · 2018–2021
▶$8.8MraisedDec 2021 · 5 investors · BiotechnologyRule 506(b)
▶$8.8MraisedDec 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karl HandelsmanDirector
- John MulliganExecutive Officer, Director, Promoter
- Nicholas WalrodDirector
- John McKearnDirector
- Diane HollenbaughExecutive Officer
- Monique SchiersingDirector
- Neela PatelExecutive Officer
- Offering amount
- $26.4M
- Amount sold
- $8.8M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$22.3MraisedMay 2020 · 6 investors · BiotechnologyRule 506(b)
▶$22.3MraisedMay 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mitchell MutzDirector
- John McKearnDirector
- Nicholas WalrodDirector
- John MulliganExecutive Officer, Director, Promoter
- Karl HandelsmanDirector
- Offering amount
- $22.3M
- Amount sold
- $22.3M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Good Therapeutics do?
- Portfolio company acquired by Roche.
- Who founded Good Therapeutics?
- Good Therapeutics was founded by John Mulligan in 2016.
- Who are Good Therapeutics's investors?
- Good Therapeutics's investors include Digitalis Ventures, RiverVest Venture Partners, Roche Venture Fund.
- How much funding has Good Therapeutics raised?
- Good Therapeutics has disclosed $31.1M raised across 2 of its 4 known rounds.
- Who acquired Good Therapeutics?
- Good Therapeutics was acquired by Roche.
- Where is Good Therapeutics headquartered?
- Good Therapeutics is headquartered in Seattle, US.